These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
451 related articles for article (PubMed ID: 12124305)
1. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Williams JA; Ring BJ; Cantrell VE; Jones DR; Eckstein J; Ruterbories K; Hamman MA; Hall SD; Wrighton SA Drug Metab Dispos; 2002 Aug; 30(8):883-91. PubMed ID: 12124305 [TBL] [Abstract][Full Text] [Related]
2. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Patki KC; Von Moltke LL; Greenblatt DJ Drug Metab Dispos; 2003 Jul; 31(7):938-44. PubMed ID: 12814972 [TBL] [Abstract][Full Text] [Related]
3. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Gorski JC; Hall SD; Jones DR; VandenBranden M; Wrighton SA Biochem Pharmacol; 1994 Apr; 47(9):1643-53. PubMed ID: 8185679 [TBL] [Abstract][Full Text] [Related]
4. Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. Yamaori S; Yamazaki H; Suzuki A; Yamada A; Tani H; Kamidate T; Fujita Ki; Kamataki T Biochem Pharmacol; 2003 Dec; 66(12):2333-40. PubMed ID: 14637191 [TBL] [Abstract][Full Text] [Related]
5. Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As. Shen L; Fitzloff JF; Cook CS Drug Metab Dispos; 2004 Feb; 32(2):186-96. PubMed ID: 14744940 [TBL] [Abstract][Full Text] [Related]
6. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Huang W; Lin YS; McConn DJ; Calamia JC; Totah RA; Isoherranen N; Glodowski M; Thummel KE Drug Metab Dispos; 2004 Dec; 32(12):1434-45. PubMed ID: 15383492 [TBL] [Abstract][Full Text] [Related]
7. Genetic contribution to variable human CYP3A-mediated metabolism. Lamba JK; Lin YS; Schuetz EG; Thummel KE Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645 [TBL] [Abstract][Full Text] [Related]
8. Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Zhao XJ; Jones DR; Wang YH; Grimm SW; Hall SD Xenobiotica; 2002 Oct; 32(10):863-78. PubMed ID: 12419016 [TBL] [Abstract][Full Text] [Related]
9. Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates. Galetin A; Brown C; Hallifax D; Ito K; Houston JB Drug Metab Dispos; 2004 Dec; 32(12):1411-20. PubMed ID: 15342470 [TBL] [Abstract][Full Text] [Related]
10. CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. Yamaori S; Yamazaki H; Iwano S; Kiyotani K; Matsumura K; Honda G; Nakagawa K; Ishizaki T; Kamataki T Drug Metab Pharmacokinet; 2004 Apr; 19(2):120-9. PubMed ID: 15499178 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the CYP3A Selective Inhibitors CYP3cide, Clobetasol, and Azamulin for Their Potential to Distinguish CYP3A7 Activity in the Presence of CYP3A4/5. Work HM; Kandel SE; Lampe JN Drug Metab Dispos; 2024 Oct; 52(11):1224-1233. PubMed ID: 38702193 [TBL] [Abstract][Full Text] [Related]
12. Comparison of steroid hormone hydroxylation mediated by cytochrome P450 3A subfamilies. Niwa T; Okamoto A; Narita K; Toyota M; Kato K; Kobayashi K; Sasaki S Arch Biochem Biophys; 2020 Mar; 682():108283. PubMed ID: 32001245 [TBL] [Abstract][Full Text] [Related]
13. Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells. Ohmori S; Nakasa H; Asanome K; Kurose Y; Ishii I; Hosokawa M; Kitada M Biochim Biophys Acta; 1998 May; 1380(3):297-304. PubMed ID: 9555064 [TBL] [Abstract][Full Text] [Related]
14. Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes. Klees TM; Sheffels P; Dale O; Kharasch ED Drug Metab Dispos; 2005 Mar; 33(3):303-11. PubMed ID: 15557344 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. Desta Z; Ward BA; Soukhova NV; Flockhart DA J Pharmacol Exp Ther; 2004 Sep; 310(3):1062-75. PubMed ID: 15159443 [TBL] [Abstract][Full Text] [Related]
16. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. Ghosal A; Satoh H; Thomas PE; Bush E; Moore D Drug Metab Dispos; 1996 Sep; 24(9):940-7. PubMed ID: 8886602 [TBL] [Abstract][Full Text] [Related]
17. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone. Mäenpää J; Hall SD; Ring BJ; Strom SC; Wrighton SA Pharmacogenetics; 1998 Apr; 8(2):137-55. PubMed ID: 10022752 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Pinto AG; Wang YH; Chalasani N; Skaar T; Kolwankar D; Gorski JC; Liangpunsakul S; Hamman MA; Arefayene M; Hall SD Clin Pharmacol Ther; 2005 Mar; 77(3):178-88. PubMed ID: 15735612 [TBL] [Abstract][Full Text] [Related]
19. Characterization of the NADPH-dependent metabolism of 17beta-estradiol to multiple metabolites by human liver microsomes and selectively expressed human cytochrome P450 3A4 and 3A5. Lee AJ; Kosh JW; Conney AH; Zhu BT J Pharmacol Exp Ther; 2001 Aug; 298(2):420-32. PubMed ID: 11454902 [TBL] [Abstract][Full Text] [Related]
20. Digging Deeper into CYP3A Testosterone Metabolism: Kinetic, Regioselectivity, and Stereoselectivity Differences between CYP3A4/5 and CYP3A7. Kandel SE; Han LW; Mao Q; Lampe JN Drug Metab Dispos; 2017 Dec; 45(12):1266-1275. PubMed ID: 28986474 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]